Close Menu

RT-PCR

Qiagen will commercialize its research-use-only AdnaTest to detect AR-V7 from liquid biopsies to investigate resistance to drugs for advanced prostate cancer.

The list includes "high throughput DNA sequence analyzer," "DNA genetic analyzer," and "mass spectrometer for clinical multiplex test systems." 

The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.

The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November. 

New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.

The RealStar Zika Virus RT-PCR Kit 1.0 has been listed by the World Health Organization as eligible for procurement agencies and member states.

The company's subsidiary Viracor-IBT can now run the real time, reverse transcriptase-PCR assay for patients meeting clinical or epidemiological criteria for Zika.

The results support the tests potential to more specifically predict high-risk prostate cancers, and lower the number of unnecessary prostate biopsies.

Japanese researchers uncovered recurrent DUX4 fusions in adolescent or young adult cases of B-cell acute lymphoblastic leukemia, along with other new ALL fusions.

With the help of TCGA sequence data, researchers uncovered expression of a long, non-coding RNA called SAMMSON that appears to be specific to melanoma.

Pages

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.